302 related articles for article (PubMed ID: 29467305)
1. CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.
Irwin DJ; Xie SX; Coughlin D; Nevler N; Akhtar RS; McMillan CT; Lee EB; Wolk DA; Weintraub D; Chen-Plotkin A; Duda JE; Spindler M; Siderowf A; Hurtig HI; Shaw LM; Grossman M; Trojanowski JQ
Neurology; 2018 Mar; 90(12):e1038-e1046. PubMed ID: 29467305
[TBL] [Abstract][Full Text] [Related]
2. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
Geng C; Tan L; Chen C
Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
[TBL] [Abstract][Full Text] [Related]
5. Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease.
Coughlin DG; Ittyerah R; Peterson C; Phillips JS; Miller S; Rascovsky K; Weintraub D; Siderowf AD; Duda JE; Hurtig HI; Wolk DA; McMillan CT; Yushkevich PA; Grossman M; Lee EB; Trojanowski JQ; Irwin DJ
Neuropathol Appl Neurobiol; 2020 Dec; 46(7):707-721. PubMed ID: 32892355
[TBL] [Abstract][Full Text] [Related]
6. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
7. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
[TBL] [Abstract][Full Text] [Related]
8. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
Howard E; Irwin DJ; Rascovsky K; Nevler N; Shellikeri S; Tropea TF; Spindler M; Deik A; Chen-Plotkin A; Siderowf A; Dahodwala N; Weintraub D; Shaw LM; Trojanowski JQ; Vaishnavi SN; Wolk DA; Mechanic-Hamilton D; Morley JF; Duda JE; Grossman M; Cousins KAQ
Neurology; 2021 Apr; 96(14):e1855-e1864. PubMed ID: 33593865
[TBL] [Abstract][Full Text] [Related]
9. Quantifying regional α -synuclein, amyloid β, and tau accumulation in lewy body dementia.
Miller RL; Dhavale DD; O'Shea JY; Andruska KM; Liu J; Franklin EE; Buddhala C; Loftin SK; Cirrito JR; Perrin RJ; Cairns NJ; Campbell MC; Perlmutter JS; Kotzbauer PT
Ann Clin Transl Neurol; 2022 Feb; 9(2):106-121. PubMed ID: 35060360
[TBL] [Abstract][Full Text] [Related]
10. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
[TBL] [Abstract][Full Text] [Related]
11. Tau pathology associates with in vivo cortical thinning in Lewy body disorders.
Spotorno N; Coughlin DG; Olm CA; Wolk D; Vaishnavi SN; Shaw LM; Dahodwala N; Morley JF; Duda JE; Deik AF; Spindler MA; Chen-Plotkin A; Lee EB; Trojanowski JQ; McMillan CT; Weintraub D; Grossman M; Irwin DJ
Ann Clin Transl Neurol; 2020 Dec; 7(12):2342-2355. PubMed ID: 33108692
[TBL] [Abstract][Full Text] [Related]
12. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
Barba L; Abu-Rumeileh S; Halbgebauer S; Bellomo G; Paolini Paoletti F; Gaetani L; Oeckl P; Steinacker P; Massa F; Parnetti L; Otto M
Neurology; 2023 Jul; 101(1):e50-e62. PubMed ID: 37188538
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
[TBL] [Abstract][Full Text] [Related]
14. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
15. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
[TBL] [Abstract][Full Text] [Related]
16. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
Sierra M; Gelpi E; Martí MJ; Compta Y
Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
[TBL] [Abstract][Full Text] [Related]
17. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.
Morenas-Rodríguez E; Alcolea D; Suárez-Calvet M; Muñoz-Llahuna L; Vilaplana E; Sala I; Subirana A; Querol-Vilaseca M; Carmona-Iragui M; Illán-Gala I; Ribosa-Nogué R; Blesa R; Haass C; Fortea J; Lleó A
Sci Rep; 2019 May; 9(1):7803. PubMed ID: 31127154
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
19. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
Nabizadeh F; Pirahesh K; Ramezannezhad E
Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]